Ann: Appendix 4D and Half Year Financial Report, page-16

If we can believe the last 4C then they hope to start at least 2 ph1 clinical trials. If that should really happen it won't have a huge impact on the sp but at least would signal that management is capable of getting things moving forward. Unless there is a miracle the oppies are dead, no way the sp gets to 2.5c - 3c without a huge announcement to get a few $ back from oppie conversion or sale.

I took a punt back then in Oct 21 and Sept 22, knew the risk but was hooked on the possibilities INV043 seemed to offer regarding cancer killing memory effect. Probably have to take a $20k loss on oppies and heads - speculation gone wrong.

Even at .5c the MC would be above $30m, comparing that to CHM and RAD with several ph1 and 2 clinical trials running and similar MC hard to imagine a quick sp turnaround.

Unlikely it will turn into a NEU over night but stranger things have happened. But realistically I have already written off the 20k.

GLTA